Pfizer And BioNTech Claim COVID-19 Vaccine Success

Interim Analysis Finds Vaccine 90% Effective, EUA Filing Expected Late November

The companies look to have secured a better than expected 90% efficacy level, but will await safety data before filing later this month.

Pfizer
Pfizer and BioNTech have produced better than expected efficacy results - but will wait for safety data before filing later this month.

Pfizer and BioNTech have announced what the world has been waiting for – positive interim Phase III results for their mRNA-based COVID-19 vaccine, BNT162b2, suggesting that it is 90% effective in preventing infection.

While the full data have yet to be published in a peer-reviewed journal, the topline result is a huge step...

Welcome to Scrip

Create an account to read this article

More from Business

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By 

Lynkuet will compete with Astellas's Veozah/Veoza

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By 

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

More from Scrip